admin

JPMorgan Chase Co. acquired a new position in shares of Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 146,767 shares of the company’s stock, valued at approximately $1,865,000. JPMorgan Chase Co. owned about 0.70% of Zynerba Pharmaceuticals as of its most […]

by

Experimental surgery: Seizure control can make an enormous difference to autistic people’s lives, regardless of its impact on diagnosis. Put simply, “seizures cause neuronal firing, and that can drown out or derail normal development of the brain,” says Anne Berg, research professor of pediatrics at Northwestern University in Chicago, Illinois. In a 2017 study, Ghatan and […]

by

Zynerba Pharmaceuticals (NASDAQ: ZYNE) stock retreated on Wednesday after serious adverse events in phase 2 clinical trial of transdermal cannabidiol gel, Zygel. The shares were weak lately as the stock has fallen over 17% in the past month and over 31% in the past three months. Investors remained concerned about the company’s future and raised […]

by

Published in the Journal of Clinical Investigation, the research conducted using Angelman syndrome animal models shows that CBD could benefit kids and adults with this serious condition, which is characterized by intellectual disability, lack of speech, brain rhythm dysfunction, and deleterious and often drug-resistant epilepsy. “There is an unmet need for better treatments for kids […]

by

Posted in: Medical Science News | Medical Research News | Medical Condition News Tags: Angelman Syndrome, Anxiety, Brain, Cannabidiol, Cannabis, Cell, Cell Biology, Clinical Trial, Disability, Efficacy, Epilepsy, Medicine, Neuroscience, Pain, Physiology, Preclinical, Research, Seizure, Sleep, Speech … read more at: https://www.news-medical.net/news/20190918/Cannabidiol-may-alleviate-seizures-and-normalize-brain-rhythms-in-Angelman-syndrome.aspx

by

SAN FRANCISCO and TEL AVIV, Israel – Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the “Company” or “Kalytera”) today announced that interim results from the Company’s Phase 2 clinical study evaluating cannabidiol (“CBD”) for the prevention of acute graft versus host disease (“GVHD”) are significantly positive, and, as a result, the Company will […]

by

In the past few months, news stories of all kinds have come out about women using marijuana during pregnancy. Part of the reason for the publicity surge around this topic is more pregnant women are opting to use it. Two separate studies released this summer showed use among pregnant women has roughly doubled from the […]

by

Jay Jenkins says he hesitated when a buddy suggested they vape CBD. “It’ll relax you,” the friend assured. The vapor that Jenkins inhaled didn’t relax him. After two puffs, he ended up in a coma. That’s because what he was vaping didn’t have any CBD, the suddenly popular compound extracted from the cannabis plant that […]

by

Patients have been left wondering how they can access medicinal cannabis in Australia…until now. Despite the Australian government approving the use of cannabis for medical purposes close to three years ago, there is still some red tape in the way of Australians getting access to the drug. A lot of the information out there can […]

by

Zynerba Pharmaceuticals (NASDAQ:ZYNE) and Millendo Therapeutics (NASDAQ:MLND) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, valuation, earnings, institutional ownership and profitability. Risk Volatility Zynerba Pharmaceuticals has a beta of 4.79, meaning that its share price is […]

by

Zynerba Pharmaceuticals (NASDAQ:ZYNE) and Millendo Therapeutics (NASDAQ:MLND) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, valuation, earnings, institutional ownership and profitability. Risk Volatility Zynerba Pharmaceuticals has a beta of 4.79, meaning that its share price is […]

by

ACB $5.270 (-3.3%) ACNNF $0.266 (12.93%) AERO $1.070 (-1.83%) AGEEF $0.227 (-2.73%) ALEAF $0.704 (-3.57%) AMMJ $0.262 (-3.32%) APHA $6.230 (-5.75%) ARNA $51.940 (-0.75%) ATT:CNX $0.080 (0%) ATTBF $0.020 (-1.25%) AUSA:CNX $0.910 (0%) AUSAF $0.692 (1.47%) AVXL $3.250 (-2.11%) BAMM:CNX $1.340 (-6.94%) BBM:CNX $0.175 (12.9%) BBRRF $0.140 (7.69%) BE:CNX $0.055 (0%) BIO:CNX $0.380 (-2.56%) BLEVF […]

by

Mohr reported from Carlsbad, California; Panama City, Florida; and Jackson, Mississippi. Contributing to this report were Allen Breed in Lexington and Ninety Six, South Carolina; Juliet Linderman in New York, Philadelphia and Towson, Maryland; Reese Dunklin in Dallas; Krysta Fauria in Carlsbad and Los Angeles; Carla K. Johnson in Seattle; Justin Pritchard in Washington and […]

by